monepantel
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT04894240)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HelminthosporiumINHIBITOR
Helminthosporium inhibitor
- Unspecified targetOTHER
Endoparasiticide for systemic use
Approved veterinary; blocks part of the nicotinic acetylcholine receptor (nematode specific sub-unit Hco-MPTL-1)
Active against all of the major gastrointestinal nematodes in sheep.
Chemistry & pharmacology
Loading structure…
SMILES
C[C@](C#N)(COc1cc(C#N)ccc1C(F)(F)F)NC(=O)c1ccc(SC(F)(F)F)cc1- Mol. weight
- 473.4 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL256563 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06177431 | Phase 1 | Jan 31, 2024 | Calvary Health Care Bethlehem, Macquarie University, PharmAust Ltd |
| NCT04894240 | Phase 1 | Dec 1, 2021 | Calvary Health Care Bethlehem, FightMND, Macquarie University, PharmAust Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Calvary Health Care Bethlehem | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Macquarie University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| PharmAust Ltd | For profit | 2 | 2 | 1 | 2021 |
| FightMND | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1